Published in Cardiovasc Drugs Ther on July 31, 2007
Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell (2009) 11.26
Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol (2008) 9.24
Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell (2008) 7.61
Necroptosis. N Engl J Med (2014) 2.71
Many stimuli pull the necrotic trigger, an overview. Cell Death Differ (2011) 2.55
The diverse role of RIP kinases in necroptosis and inflammation. Nat Immunol (2015) 2.36
Cell biology of ischemia/reperfusion injury. Int Rev Cell Mol Biol (2012) 2.24
Two independent pathways of regulated necrosis mediate ischemia-reperfusion injury. Proc Natl Acad Sci U S A (2013) 2.10
Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models. Cell Death Dis (2012) 1.94
Mechanism of Siglec-8-mediated cell death in IL-5-activated eosinophils: role for reactive oxygen species-enhanced MEK/ERK activation. J Allergy Clin Immunol (2013) 1.69
Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci U S A (2014) 1.62
An Sp1 transcription factor coordinates caspase-dependent and -independent apoptotic pathways. Nature (2013) 1.61
Over-expression of a modified bifunctional apoptosis regulator protects against cardiac injury and doxorubicin-induced cardiotoxicity in transgenic mice. Cardiovasc Res (2008) 1.52
Neuronal cell death in neonatal hypoxia-ischemia. Ann Neurol (2011) 1.47
Going up in flames: necrotic cell injury and inflammatory diseases. Cell Mol Life Sci (2010) 1.35
The complex interplay between autophagy, apoptosis, and necrotic signals promotes T-cell homeostasis. Immunol Rev (2010) 1.35
RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation. PLoS One (2011) 1.33
The cardioprotective effect of necrostatin requires the cyclophilin-D component of the mitochondrial permeability transition pore. Cardiovasc Drugs Ther (2007) 1.32
Dichotomy between RIP1- and RIP3-mediated necroptosis in tumor necrosis factor-α-induced shock. Mol Med (2012) 1.31
Programmed necrosis in the cross talk of cell death and inflammation. Annu Rev Immunol (2014) 1.27
CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress-induced myocardial necroptosis. Nat Med (2016) 1.09
New components of the necroptotic pathway. Protein Cell (2012) 1.04
Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models. Cell Death Differ (2012) 1.04
Discovery of Small Molecule RIP1 Kinase Inhibitors for the Treatment of Pathologies Associated with Necroptosis. ACS Med Chem Lett (2013) 1.04
Fueling the flames: Mammalian programmed necrosis in inflammatory diseases. Cold Spring Harb Perspect Biol (2012) 1.03
Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog (2014) 1.01
Necrostatin-1 attenuates mitochondrial dysfunction in neurons and astrocytes following neonatal hypoxia-ischemia. Neuroscience (2012) 1.00
Transforming growth factor β-activated kinase 1 signaling pathway critically regulates myocardial survival and remodeling. Circulation (2014) 0.99
RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ (2016) 0.98
New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases. World J Gastroenterol (2014) 0.96
Necrosis-dependent and independent signaling of the RIP kinases in inflammation. Cytokine Growth Factor Rev (2013) 0.95
The prevalence of TNFα-induced necrosis over apoptosis is determined by TAK1-RIP1 interplay. PLoS One (2011) 0.94
miR-874 regulates myocardial necrosis by targeting caspase-8. Cell Death Dis (2013) 0.94
PEDF and PEDF-derived peptide 44mer protect cardiomyocytes against hypoxia-induced apoptosis and necroptosis via anti-oxidative effect. Sci Rep (2014) 0.94
The mechanism of necroptosis in normal and cancer cells. Cancer Biol Ther (2013) 0.93
Shikonin kills glioma cells through necroptosis mediated by RIP-1. PLoS One (2013) 0.93
Release of interleukin-1α or interleukin-1β depends on mechanism of cell death. J Biol Chem (2014) 0.93
Cell death in the myocardium: my heart won't go on. IUBMB Life (2013) 0.92
Chronicles of a death foretold: dual sequential cell death checkpoints in TNF signaling. Cell Cycle (2010) 0.91
Role of the mitochondrion in programmed necrosis. Front Physiol (2010) 0.90
Small molecules, big effects: the role of microRNAs in regulation of cardiomyocyte death. Cell Death Dis (2014) 0.88
Regulated necrotic cell death: the passive aggressive side of Bax and Bak. Circ Res (2015) 0.87
RIP1 kinase mediates arachidonic acid-induced oxidative death of oligodendrocyte precursors. Int J Physiol Pathophysiol Pharmacol (2010) 0.87
Programmed Necrosis: A Prominent Mechanism of Cell Death following Neonatal Brain Injury. Neurol Res Int (2012) 0.85
Cell death signalling mechanisms in heart failure. Exp Clin Cardiol (2011) 0.85
Pax2 regulates a fadd-dependent molecular switch that drives tissue fusion during eye development. Hum Mol Genet (2012) 0.85
Nec-1 enhances shikonin-induced apoptosis in leukemia cells by inhibition of RIP-1 and ERK1/2. Int J Mol Sci (2012) 0.83
Structure-activity relationship and liver microsome stability studies of pyrrole necroptosis inhibitors. Bioorg Med Chem Lett (2008) 0.82
Combination of necroptosis and apoptosis inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury. J Anesth (2013) 0.82
Endothelial necrosis at 1 hour postburn predicts progression of tissue injury. Wound Repair Regen (2013) 0.81
NO donor induces Nec-1-inhibitable, but RIP1-independent, necrotic cell death in pancreatic β-cells. FEBS Lett (2011) 0.81
Increased hepatic receptor interacting protein kinase 3 expression due to impaired proteasomal functions contributes to alcohol-induced steatosis and liver injury. Oncotarget (2016) 0.79
Optimization of tricyclic Nec-3 necroptosis inhibitors for in vitro liver microsomal stability. Bioorg Med Chem Lett (2012) 0.79
Necroptotic cell death in failing heart: relevance and proposed mechanisms. Heart Fail Rev (2016) 0.78
PARP-1 hyperactivation and reciprocal elevations in intracellular Ca2+ during ROS-induced nonapoptotic cell death. Toxicol Sci (2014) 0.78
The role of inflammation and cell death in the pathogenesis, progression and treatment of heart failure. Heart Fail Rev (2016) 0.78
Ischemia/Reperfusion. Compr Physiol (2016) 0.78
Active MLKL triggers the NLRP3 inflammasome in a cell-intrinsic manner. Proc Natl Acad Sci U S A (2017) 0.77
Necrostatin-1 protection of dopaminergic neurons. Neural Regen Res (2015) 0.77
Ensembling and filtering: an effective and rapid in silico multitarget drug-design strategy to identify RIPK1 and RIPK3 inhibitors. J Mol Model (2015) 0.77
Role of necroptosis in the pathogenesis of solid organ injury. Cell Death Dis (2015) 0.77
Novel therapeutic strategies for ischemic heart disease. Pharmacol Res (2014) 0.77
Protein Kinase Signaling at the Crossroads of Myocyte Life and Death in Ischemic Heart Disease. Drug Discov Today Ther Strateg (2012) 0.76
Necroptosis, a novel type of programmed cell death, contributes to early neural cells damage after spinal cord injury in adult mice. J Spinal Cord Med (2014) 0.76
The role of RIP1 and RIP3 in the development of aplastic anemia induced by cyclophosphamide and busulphan in mice. Int J Clin Exp Pathol (2014) 0.75
Necroptosis is a key mediator of enterocytes loss in intestinal ischaemia/reperfusion injury. J Cell Mol Med (2016) 0.75
Complex Pathologic Roles of RIPK1 and RIPK3: Moving Beyond Necroptosis. Trends Pharmacol Sci (2017) 0.75
Pore-forming toxin-mediated ion dysregulation leads to death receptor-independent necroptosis of lung epithelial cells during bacterial pneumonia. Cell Death Differ (2017) 0.75
Ensemble pharmacophore meets ensemble docking: a novel screening strategy for the identification of RIPK1 inhibitors. J Comput Aided Mol Des (2014) 0.75
Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet (2007) 3.93
Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation (2010) 3.72
New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res (2004) 3.63
Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med (2015) 3.60
Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res (2002) 2.84
Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest (2013) 2.83
Transient limb ischemia induces remote preconditioning and remote postconditioning in humans by a K(ATP)-channel dependent mechanism. Circulation (2007) 2.75
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes (2005) 2.64
Remote ischaemic preconditioning: underlying mechanisms and clinical application. Cardiovasc Res (2008) 2.37
Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res (2006) 2.30
Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res (2004) 2.25
Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res (2003) 2.25
Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res (2010) 2.20
Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol (2004) 2.18
Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev (2007) 2.14
Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res (2007) 2.01
Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol (2008) 1.95
The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med (2005) 1.88
Remote ischaemic preconditioning involves signalling through the SDF-1α/CXCR4 signalling axis. Basic Res Cardiol (2013) 1.88
STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem (2003) 1.79
Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol (2011) 1.74
Preconditioning and postconditioning: underlying mechanisms and clinical application. Atherosclerosis (2008) 1.74
Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res (2013) 1.72
Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol (2005) 1.71
Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress. Am J Physiol Heart Circ Physiol (2007) 1.70
Preconditioning protects by inhibiting the mitochondrial permeability transition. Am J Physiol Heart Circ Physiol (2004) 1.69
Effect of remote ischemic preconditioning on acute kidney injury in nondiabetic patients undergoing coronary artery bypass graft surgery: a secondary analysis of 2 small randomized trials. Am J Kidney Dis (2010) 1.68
Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. J Mol Cell Cardiol (2003) 1.68
Photoaffinity labeling of nicotinic acid adenine dinucleotide phosphate (NAADP) targets in mammalian cells. J Biol Chem (2011) 1.67
The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol (2009) 1.66
New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation (2011) 1.66
Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J (2013) 1.65
Preconditioning the diabetic heart: the importance of Akt phosphorylation. Diabetes (2005) 1.62
Mitochondrial uncoupling, with low concentration FCCP, induces ROS-dependent cardioprotection independent of KATP channel activation. Cardiovasc Res (2006) 1.56
Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial. Heart (2011) 1.55
Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol (2005) 1.54
The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol (2011) 1.53
'Conditioning' the heart during surgery. Eur J Cardiothorac Surg (2009) 1.51
Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res (2004) 1.46
Enrichment of neonatal rat cardiomyocytes in primary culture facilitates long-term maintenance of contractility in vitro. Am J Physiol Cell Physiol (2012) 1.46
Preconditioning and postconditioning: united at reperfusion. Pharmacol Ther (2007) 1.45
The mitochondrial permeability transition pore: its fundamental role in mediating cell death during ischaemia and reperfusion. J Mol Cell Cardiol (2003) 1.44
Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse. Circ Res (2008) 1.44
Is this truly ischemic preconditioning? Circ Res (2006) 1.41
The neural and humoral pathways in remote limb ischemic preconditioning. Basic Res Cardiol (2010) 1.40
Premature meta-analysis of remote ischemic preconditioning. Am J Cardiol (2009) 1.38
Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol (2007) 1.38
Translating novel strategies for cardioprotection: the Hatter Workshop Recommendations. Basic Res Cardiol (2010) 1.37
Morphine peripheral analgesia depends on activation of the PI3Kgamma/AKT/nNOS/NO/KATP signaling pathway. Proc Natl Acad Sci U S A (2010) 1.34
Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol (2003) 1.33
Statins and cardioprotection--more than just lipid lowering? Pharmacol Ther (2009) 1.27
Apelin-13 and apelin-36 exhibit direct cardioprotective activity against ischemia-reperfusion injury. Basic Res Cardiol (2007) 1.27
Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Eur Heart J (2010) 1.26
Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol (2003) 1.23
Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc Drugs Ther (2005) 1.22
The novel adipocytokine visfatin exerts direct cardioprotective effects. J Cell Mol Med (2008) 1.21
Time to take myocardial reperfusion injury seriously. N Engl J Med (2008) 1.20
Hydrogen sulfide improves neutrophil migration and survival in sepsis via K+ATP channel activation. Am J Respir Crit Care Med (2010) 1.19
B-type natriuretic peptide limits infarct size in rat isolated hearts via KATP channel opening. Am J Physiol Heart Circ Physiol (2003) 1.19
Mitochondrial permeability transition pore as a target for cardioprotection in the human heart. Am J Physiol Heart Circ Physiol (2005) 1.18
Cardiac preconditioning for ischaemia: lost in translation. Dis Model Mech (2010) 1.18
Mitochondrial K(ATP) channels: role in cardioprotection. Cardiovasc Res (2002) 1.17
Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury. Am J Physiol Heart Circ Physiol (2011) 1.17
Retracted STAT-1 facilitates the ATM activated checkpoint pathway following DNA damage. J Cell Sci (2005) 1.17
Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid Redox Signal (2010) 1.17
Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther (2007) 1.16
PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol (2002) 1.14
p53 down-regulation: a new molecular mechanism involved in ischaemic preconditioning. FEBS Lett (2003) 1.14
Slow calcium waves and redox changes precede mitochondrial permeability transition pore opening in the intact heart during hypoxia and reoxygenation. Cardiovasc Res (2011) 1.13
Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol (2009) 1.13
The second window of preconditioning (SWOP) where are we now? Cardiovasc Drugs Ther (2010) 1.12
Effect of remote ischemic preconditioning on clinical outcomes in patients undergoing coronary artery bypass graft surgery (ERICCA): rationale and study design of a multi-centre randomized double-blinded controlled clinical trial. Clin Res Cardiol (2011) 1.08
Transitory activation of AMPK at reperfusion protects the ischaemic-reperfused rat myocardium against infarction. Cardiovasc Drugs Ther (2010) 1.07
Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol (2002) 1.07
Postconditioning protects against endothelial ischemia-reperfusion injury in the human forearm. Circulation (2006) 1.06
Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther (2013) 1.06
Heat shock protein 27 protects the heart against myocardial infarction. Basic Res Cardiol (2004) 1.06
Local control of nuclear calcium signaling in cardiac myocytes by perinuclear microdomains of sarcolemmal insulin-like growth factor 1 receptors. Circ Res (2012) 1.06
Cardioprotective growth factors. Cardiovasc Res (2009) 1.05
The multifaceted photocytotoxic profile of hypericin. Mol Pharm (2009) 1.05
Mitochondrial cyclophilin-D as a potential therapeutic target for post-myocardial infarction heart failure. J Cell Mol Med (2011) 1.03
Cardioprotection during cardiac surgery. Cardiovasc Res (2012) 1.03
Postconditioning protects human atrial muscle through the activation of the RISK pathway. Basic Res Cardiol (2007) 1.03
Ischemic preconditioning targets the reperfusion phase. Basic Res Cardiol (2007) 1.03
Leptin-induced cardioprotection involves JAK/STAT signaling that may be linked to the mitochondrial permeability transition pore. Am J Physiol Heart Circ Physiol (2010) 1.03
Postconditioning: a simple, clinically applicable procedure to improve revascularization in acute myocardial infarction. Circulation (2005) 1.02